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Abstract
This study aimed to determine the prognostic value of cardiovascular magnetic resonance (CMR) in patients with heart 
failure with preserved ejection fraction and associated pulmonary hypertension (pulmonary hypertension-HFpEF). Patients 
with pulmonary hypertension-HFpEF were recruited from the ASPIRE registry and underwent right heart catheterisa-
tion (RHC) and CMR. On RHC, the inclusion criteria was a mean pulmonary artery pressure (MPAP) ≥ 25 mmHg and 
pulmonary arterial wedge pressure > 15 mmHg and, on CMR, a left atrial volume > 41 ml/m2 with left ventricular ejection 
fraction > 50%. Cox regression was performed to evaluate CMR against all-cause mortality. In this study, 116 patients with 
pulmonary hypertension-HFpEF were identified. Over a mean follow-up period of 3 ± 2 years, 61 patients with pulmonary 
hypertension-HFpEF died (53%). In univariate regression, 11 variables demonstrated association to mortality: indexed right 
ventricular (RV) volumes and stroke volume, right ventricular ejection fraction (RVEF), indexed RV mass, septal angle, 
pulmonary artery systolic/diastolic area and its relative area change. In multivariate regression, only three variables were 
independently associated with mortality: RVEF (HR 0.64, P < 0.001), indexed RV mass (HR 1.46, P < 0.001) and IV septal 
angle (HR 1.48, P < 0.001). Our CMR model had 0.76 area under the curve (P < 0.001) to predict mortality. This study con-
firms that pulmonary hypertension in patients with HFpEF is associated with a poor prognosis and we observe that CMR 
can risk stratify these patients and predict all-cause mortality. When patients with HFpEF develop pulmonary hypertension, 
CMR measures that reflect right ventricular afterload and function predict all-cause mortality.
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Introduction
Heart failure with preserved ejection fraction (HFpEF) now 
constitutes approximately half of all heart failure (HF) diag-
noses [1]. It is estimated that approximately 50% of patients 
with HFpEF develop pulmonary hypertension [2, 3]. The 
development of pulmonary hypertension in HFpEF is mainly 
due to raised left ventricular filling pressures, which causes 
a sustained backward hemodynamic transmission to the pul-
monary vascular bed. In patients with HFpEF, the develop-
ment of pulmonary hypertension predicts a worse prognosis 
[2, 4].
Cardiovascular magnetic resonance (CMR) is the imaging 
reference standard for volumetric assessment and is emerg-
ing as one of the key non-invasive imaging methods to 
diagnose, and temporally monitor patients with pulmonary 
hypertension [5, 6] and phenotype patients with HFpEF [7]. 
The guidelines for the diagnosis and treatment of pulmonary 
hypertension highlight the potential of CMR in the assess-
ment of disease severity and follow-up [8–10].
Cardiac MR provides added value to the clinical assess-
ment in the prognostic evaluation of patients with pulmonary 
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arterial hypertension [11] and allows for improved risk strat-
ification of patients with PAH when used in conjunction 
with the REVEAL 2.0 and the modified French Pulmonary 
Hypertension Registry risk score [12]. In HFpEF, CMR 
can also sub-phenotype myocardial diseases that lead to the 
development of myocardial stiffness [13], including cardiac 
amyloidosis, hypertensive cardiomyopathy, hypertrophic 
cardiomyopathy and cardiac sarcoidosis.
Currently, there are limited outcome data in advanced 
stages of HFpEF using CMR, especially in patients with 
pulmonary hypertension-HFpEF. In addition, it remains 
unknown if CMR can be used in this patient population to 
risk stratify patients and predict prognosis [9].
The aim of this study was to investigate if non-contrast 
enhanced cine and flow CMR could risk stratify patients 
with pulmonary hypertension-HFpEF and inform prognosis.
Methods
This study was approved by the National Research Eth-
ics Service (16/YH/0352) in the UK. The study complied 
with the Declaration of Helsinki. Patients were identified 
from the ASPIRE registry [14] and underwent a detailed 
assessment including blood, lung function, exercise test-
ing, multimodality imaging and right heart catheterisation 
as previously described [14, 15]. Consecutive patients with 
suspected pulmonary hypertension who underwent CMR 
from April 2012 to April 2017 were assessed for inclusion 
in the study. All patients were recruited at Sheffield Teaching 
Hospitals NHS Foundation Trust. Inclusion criteria included 
age ≥ 18 years and a confirmed diagnosis of pulmonary 
hypertension-HFpEF. A diagnosis of pulmonary hyper-
tension-HFpEF required a mean pulmonary arterial pres-
sure (mPAP) ≥ 25 mmHg with a pulmonary artery wedge 
pressure (PCWP) > 15 mmHg at right heart catheterisation 
(RHC) and a left ventricular ejection fraction > 50% with 
a left atrial volume index > 41 ml/m2 on CMR [16]. Right 
heart catheterisation was performed using a balloon-tipped 
7.5Fr thermodilution catheter (Becton-Dickinson, Franklin 
Lakes, New Jersey). The mean pulmonary arterial pressure 
and pulmonary artery wedge pressure were recorded using 
standard techniques described previously [17]. Patients with 
other forms of pulmonary hypertension were excluded.
CMR acquisition
CMR was performed on a GE HDx 1.5-T system (GE 
Healthcare, Milwaukee, Wisconsin) using an 8-channel 
cardiac coil.
The protocol included four-chamber (4Ch) and short-
axis (SA) cine images, acquired using a retrospectively car-
diac gated multi-slice steady-state free precession (SSFP) 
sequence. We acquired a stack of axial images in the short 
axis (SA) plane, with a slice thickness of 10 mm with no 
inter-slice gap or 8 mm with a 2 mm inter-slice gap, from the 
base to the apex of both ventricles. Time-resolved images of 
the pulmonary artery were performed using a retrospectively 
cardiac gated SSFP sequence with a single slice of 10 mm 
taken perpendicular to the long-axis of the pulmonary 
artery. The SSFP sequence parameters were: TR 2.8 ms, 
TE 1.0 ms, flip angle 50°, field of view 48 × 48, 256 × 256 
matrix and125 kHz bandwidth.
CMR image analysis
CMR images were manually analysed on GE Advantage 
Workstation ReportCard software, by an experienced 
radiographer (DC). All segmentation was done manually. 
Ventricular volumetric assessment was performed as per 
guidelines [18] (S-Fig. 1–2). All volume parameters were 
indexed to body surface area. Metrics included: the indexed 
left ventricular end-diastolic volume (LVEDVi), end-systolic 
volume (LVESVi), stroke volume (LVSVi), left ventricular 
ejection fraction (LVEF), right ventricular end-diastolic vol-
ume (RVEDVi), end-systolic volume (RVESVi), stroke vol-
ume (RVSVi) and right ventricular ejection fraction (RVEF). 
Left atrial volume indexed was calculated using the biplane 
area-length method [19]. The interventricular (IV) septal 
angle were measured as previously described [20]. Maximal 
and minimal pulmonary arterial (PA) areas were manually 
traced, and relative area change (RAC) was defined by the 
following equation: PA RAC: (maximum area–minimum 
area) /minimum area [21]. Reproducibility for these CMR 
metrics have been previously published by our group [11, 
20].
Statistics
Statistical analysis was performed using SPSS statistics 22 
(IBM, Chicago). All continuous variables are presented as 
mean (standard deviation). Independent T-test was used 
to compare the clinical and CMR variables in alive/dead 
patients. For categorical comparisons, the Chi-square test 
was used. Further details on statistical analysis are in the 




The baseline demographics of the 116 patients with pulmo-
nary hypertension-HFpEF who met the inclusion criteria are 
shown in Table 1. The average age was 73 ± 7 years and 57% 
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of patients were female. During the mean follow-up period 
of 3 ± 2 years, 61 patients with pulmonary hypertension-
HFpEF died (53%).
Left heart volumetric assessment
Left atrial volume index was significantly higher in the 
patients who were dead at the census (80.3 ± 31.2 ml/m2 vs 
66.5 ± 19.1 ml/m2, P = 0.005), whereas, there were no sig-
nificant differences in LV volumes (LVEDVi, LVESVi), LV 
systolic function assessed by LVEF, LV stroke volume index 
or LV mass (indexed) (Supplementary Table 1).
Right heart volumetric assessment
Right ventricular volumetric parameters including RVESVi, 
RV mass and interventricular septal angle were significantly 
higher (P < 0.005) and RVEF significantly lower (P = 0.002) 
in patients with pulmonary hypertension-HFpEF who were 
dead compared to those alive at the census date (Fig. 1A).
Pulmonary artery area
The PA diastolic area was significantly increased (P = 0.003). 
PA systolic area was increased (P = 0.016) and PA relative 
area change reduced (P = 0.027) in patients who were dead 
compared to those alive at the census data.
At the univariate analysis of demographic and CMR vari-
ables, 11 were associated with mortality (Supplementary 
Table 2). In a forward selection, multivariate cox regression 
model, only three parameters demonstrated independent 
association to all-cause mortality in this patient population. 
These included the CMR parameters–RVEF (HR 0.64, 95% 
CI 0.47 to 0.87, P < 0.001), indexed RV mass (HR 1.46, 95% 
CI 1.18 to 1.8, P < 0.001) and IV septal angle (HR 1.48, 95% 
CI 1.12 to 1.94, P < 0.001) (Fig. 1).
Pulmonary hypertension-HFpEF with RVEF less than 
or equal to 49% had a worse survival at 1-year (70% vs 
96%), 3-years (44% vs 73%) and 5-years (26% vs 64%), 
than patients with a RVEF > 49%, respectively (P = 0.0001) 
(Fig. 2). In patients with an indexed RV mass > 17 g/m2 
patients had a worse survival at 1-year (71% vs. 93%), 
3-years (39% vs. 76%) and at 5-years (30% vs. 60%) than 
patients with indexed RV mass <  = 17 g/m2 (P = 0.0002). 
Patients with an inter-ventricular septal angle > 139° had 
a worse survival at 1-year (71% vs. 90%), 3-years (31% 
vs. 74%) and at 5-years (25% vs. 54%) than patients with 
an inter-ventricular septal angle <  = 139° (P = 0.0001). 
Receiver operating characteristic analysis are detailed in 
Table 2 and the supplementary document.
A score was developed defined by thresholds from 
receiver operator characteristic (ROC) analysis. The mini-
mum score was set at 0 which meant all the three variables 
were not above their threshold. The maximum score was 3 
which meant all the three variables were above their thresh-
old. The CMR score model demonstrated a higher area under 
the curve than the three variables individually at 0.76, 95% 
CI 0.67 to 0.83, P < 0.001. The overall sensitivity, specificity 
and accuracy of a pulmonary hypertension-HFpEF CMR 
score > 2 for predicting all-cause mortality were 72% (95% 
CI 59.2–82.9), 71% (95% CI 57.1–82.4) and 71.5% (95% CI 
62.4–79.5) respectively (Fig. 2).
Discussion
In this study we have shown that a CMR based volumet-
ric and functional assessment of the right ventricle can risk 
stratify patients with pulmonary hypertension-HFpEF. In 
addition, we have presented a simple CMR scoring model 
incorporating independent predictors of outcome RV EF, 
Table 1  Study demographics and pulmonary haemodynamics
Categorical comparisons done by Chi-square test
BMI Body mass index, IHD Ischaemic heart disease, RA right atrial, 
PAP pulmonary artery pressure, PCWP pulmonary capillary wedge 
pressure, DPG diastolic pulmonary gradient, TPG transpulmonary 
pressure gradient, PVR pulmonary vascular resistance
* P-value is for T-Test comparison between Alive and Dead cohorts
All Alive Dead P-value*
 N 116 55 61
 Age (yrs) 73 ± 7 71 ± 8 75 ± 7 0.018
 Gender (Male) 50 (43%) 15 (27%) 35 (57%) 0.001
 BMI (kg/m2) 31 ± 6 31 ± 7 30 ± 6 0.284
 Heart rate (bpm) 65 ± 12 65 ± 13 65 ± 11 0.800
 Diabetes mellitus 30 (26%) 13 (24%) 17 (28%) 0.607
 Hypercholesterol-
aemia
24 (21%) 11 (20%) 13 (21%) 0.863
 Hypertension 78 (67%) 41 (75%) 37 (61%) 0.056
 IHD 20 (17%) 9 (16%) 11 (18%) 0.814
 Atrial fibrillation 82 (71%) 32 (58%) 50 (82%) 0.009
 Stroke 8 (7%) 3 (5%) 5 (8%) 0.565
 Invasive haemodynamics
  Mean RA (mmHg) 15 ± 5 14 ± 5 17 ± 5 0.004
  Mean PAP (mmHg) 42 ± 10 39 ± 9 45 ± 10 0.002
  PCWP (mmHg) 23 ± 5 23 ± 5 22 ± 5 0.327
  DPG (mmHg) 1 ± 7 -1 ± 6 3 ± 7  < 0.001
  TPG (mmHg) 19 ± 9 16 ± 7 22 ± 9  < 0.001
  Cardiac index (L/
min/m2)
2.8 ± 1 2.9 ± 1.1 2.7 ± 0.8 0.432
  PVR (Wood unit) 4.2 ± 2.95 3.16 ± 1.7 5 ± 3.5  < 0.001
  O2 saturation (arte-
rial)
95 ± 4 95 ± 3 94 ± 4 0.071
  O2 saturation 
(venous)
65 ± 9 68 ± 8 63 ± 10 0.005
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indexed RV mass and IV septal angle. Our study highlights 
the potential value of CMR in the prognostic assessment of 
patients with pulmonary hypertension-HFpEF.
Echocardiography is a first-line diagnostic imaging 
test for patients presenting with symptoms and signs of 
HF [22]. Several studies have demonstrated that echo-
cardiographic measures reflecting RV function predict 
prognosis in pulmonary hypertension-HFpEF [2, 23–25]. 
It is worth noting that the majority of echocardiography-
based studies have demonstrated that it is mainly RV 
function and remodelling that are associated with a poor 
prognosis in pulmonary hypertension-HFpEF. In a study 
which recruited 419 patients with HFpEF, Burke et al. 
demonstrated that LV compliance and also RV hypertro-
phy (hazard ratio = 1.37; P < 0.001), were most predic-
tive of worse outcomes [24]. Similar to our study, neither 
LV function nor any other LV volumetric parameter was 
independently associated with cardiovascular outcomes. 
In another large study of 562 patients which assessed 
RV function in a semiquantitative way, Mohammed et al. 
demonstrated that the presence of impaired RV function 
was associated with higher all-cause mortality (hazard 
ratio = 1.35; P = 0.03) [23]. It is worth noting that even 
though echocardiography is a good screening imaging 
modality, evaluation of right heart remains challenging 
and limited. Moreover, almost 10–15% patients can have 
Fig. 1  Panel a Illustration of study case. There is RV hypertrophy with reduced RV function (RV EF 40%) and the septal angle is 190°. Panel b 
Mean plots for RV EF, indexed mass and septal angle. Panel c Scatter plots for the three variables against time-to-death
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non-diagnostic studies due to poor acoustic windows. The 
role of CMR is not only to clarify the diagnosis, but also 
monitor disease process longitudinally. CMR uniquely 
allows one to quantify RV mass precisely, which cannot 
Fig. 2  Panel aKaplan-Meier survival curves. Panel b CMR score model predicts survival in pulmonary hypertension-HFpEF. Panel c Kaplan–
Meier survival curve results for the HFpEF-PH CMR score
Table 2  C-statistics
AUC area under the curve, CI confidence interval, RV EF Right ventricular ejection fraction, IV intra-ventricular, CMR cardiac magnetic reso-
nance
a Significantly different to CMR model AUC 
b Youden index derived
AUC 95% CI P Criterionb Sensitivity (95% CI) Specificity (95% CI)
RV EF (%) 0.67a 0.57 to 0.75  < 0.01  ≤ 49 75 (63–85.5) 58 (44–71)
Indexed RV mass (grams/m2) 0.70 0.61 to 0.78  < 0.01  > 17 67 (54–79) 62 (48–75)
IV septal angle (˚) 0.67a 0.58 to 0.76  < 0.01  > 139 57 (44–70) 76 (63–87)
CMR model 0.76 0.67 to 0.83  < 0.01  > 1 72 (59–83) 71 (57–82)
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be done by echocardiography. Hence, CMR is the refer-
ence standard for the evaluation of right cardiac volumes 
and function [26].
It is established that RV dysfunction on CMR predicts 
outcomes in pulmonary arterial hypertension [27]. The find-
ings of this study are broadly consistent with Aschauer et al. 
who also demonstrated that right ventricular systolic dys-
function by CMR is independently associated with mortality 
in HFpEF [28]. However, the main differences between their 
work and this study are that they recruited generic HFpEF 
patients where as in this study we only recruited patients 
who had developed PH-HFpEF. Hence, it is plausible to 
conclude that this study has recruited more severe cases of 
HFpEF, who have subsequently developed PH. In addition, 
this study has evaluated RV functional and anatomy compre-
hensively including septal angle which demonstrated inde-
pendent prognostic role in patients with PH-HFpEF.
In this study, we have also developed a simplified scoring 
tool based on three CMR metrics which may aid risk strati-
fication of patients with pulmonary hypertension-HFpEF. 
The CMR score is simple and easy to integrate in routine 
practice. Patients with CMR score > 2, could be offered more 
regular clinical monitoring as evidence suggests that a strat-
egy to reduce the pulmonary artery pressure primarily by 
diuretic therapy can improve outcomes in these patients [29, 
30]. Hence, a non-invasive CMR model which can appro-
priately risk stratify patients by assessing right ventricular 
function and the severity of pre-capillary pulmonary hyper-
tension may be of value in clinical trials of new therapies 
or treatment approaches including closer monitoring and 
optimisation of heart failure in high-risk patients.
Limitations
Patients were required to have a cardiac catheterisation to 
identify patients with HFpEF with pulmonary hyperten-
sion. The results of our study, therefore, apply to a selected 
cohort, however, this has the advantage of using reference 
standard haemodynamic measures to define pulmonary 
hypertension-HFpEF. HFpEF patients with a detectable 
scar, fibrosis on T1-mapping, myocardial ischaemia or 
right ventricular impairment appear to have a worse prog-
nosis [31, 32]. In our study, we only evaluated CMR cine 
related parameters. Further studies are needed to evaluate 
prognostic role of multi-parametric mapping in pulmonary 
hypertension-HFpEF. However, we feel the current CMR 
model has value in patients who either have contraindication 
for gadolinium contrast agent or are due to have a shorter 
CMR scan for monitoring of function. Finally, this study did 
not record echocardiography data to evaluate incremental 
role of CMR.
Conclusion
In this study, we observed that CMR can risk stratify pul-
monary hypertension-HFpEF patients and predict all-cause 
mortality. When patients develop pulmonary hypertension 
associated with HFpEF, it is primarily right heart function 
and imaging features of pre-capillary pulmonary hyperten-
sion which predict mortality.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s10554- 021- 02279-z.
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